In this episode of The Human Upgrade, Dave Asprey interviews Len May, CEO of EndoDNA, about the role of genetics in health, cannabis use, and responses to pharmaceuticals and psychedelics. Len explains the endocannabinoid system and how genetic testing can help individuals understand their predispositions to adverse effects from cannabis and other substances. They discuss the importance of personalized medicine, the limitations of generalized health advice, and the need for consistent product standards in the cannabis industry. They also touch on GLP-1s for weight loss and longevity, the significance of pharmacogenomics, and the value of genetic testing for understanding individual responses to various treatments and substances. Len offers a discount code "Len25" for listeners to try EndoDNA's services.
Sign in to continue reading, translating and more.
Continue